Amyloid-associated depression: A prodromal depression of Alzheimer disease?

Archives of General Psychiatry

Volumn 65, Issue 5, 2008, Pages 542-550

  Sun, Xiaoyan ^a,b   Steffens, David C ^c   Au, Rhoda ^d   Folstein, Marshal ^a,b   Summergrad, Paul ^a   Yee, Jacqueline ^b   Rosenberg, Irwin ^e   Mwamburi, D Mkaya ^a   Wei, Qiao Qiu ^a,b,f  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TUFTS UNIVERSITY   (United States)

^f TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ANTIDEPRESSANT AGENT;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DEPRESSION; DRUG USE; FEMALE; HOME CARE; HUMAN; LANGUAGE; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MULTIVARIATE ANALYSIS; PROTEIN BLOOD LEVEL; UNIVARIATE ANALYSIS;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MEMORY DISORDERS; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; PREVALENCE; SEVERITY OF ILLNESS INDEX;

EID: 43149101276     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.65.5.542     Document Type: Article

References (63)

1. 1-42 and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 2006;5(8):655-660.
2. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG. Association of low plasma Aβ42/Aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease [published correction appears in Arch Neurol. 2007;64(9):1246]. Arch Neurol. 2007;64(3):354-362.
3. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry. 2006;63(5):530-538.
4. Qiu WQ, Sun X, Selkoe DJ, Mwamburi DM, Huang T, Bhadela R, Bergethon P, Scott TM, Summergrad P, Wang L, Rosenberg I, Folstein M. Depression is associated with low plasma Aβ42 independently of cardiovascular disease in the homebound elderly. Int J Geriatr Psychiatry. 2007;22(6):536-542.
5. Iwatsubo T. Amyloid beta protein in plasma as a diagnostic marker for Alzheimer's disease. Neurobiol Aging. 1998;19(2):161-163.
6. Pomara N, Willoughby LM, Sidtis JJ, Mehta PD. Selective reductions in plasma Aβ 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report. Am J Geriatr Psychiatry. 2005;13(10):914-917.
7. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21(2):372-381.
8. DeMattos RB, Bales KR, Parsadanian M, O'Dell MA, Foss EM, Paul SM, Holtzman DM. Plaque-associated disruption of CSF and plasma amyloid-beta (Aβ) equilibrium in a mouse model of Alzheimer's disease. J Neurochem. 2002;81(2):229-236.
9. van Dijk EJ, Prins ND, Vermeer SE, Hofman A, van Duijn CM, Koudstaal PJ, Breteler MM. Plasma amyloid beta, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann Neurol. 2004;55(4):570-575.
10. Gurol ME, Irizarry MC, Smith EE, Raju S, Diaz-Arrastia R, Bottiglieri T, Rosand J, Growdon JH, Greenberg SM. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology. 2006;66(1):23-29.
11. Dal Forno G, Palermo MT, Donohue JE, Karagiozis H, Zonderman AB, Kawas CH. Depressive symptoms, sex, and risk for Alzheimer's disease. Ann Neurol. 2005;57(3):381-387.
12. Steffens DC, Plassman BL, Helms MJ, Welsh-Bohmer KA, Saunders AM, Breitner JC. A twin study of late-onset depression and apolipoprotein E ε4 as risk factors for Alzheimer's disease. Biol Psychiatry. 1997;41(8):851-856.
13. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
14. Bright P, Jaldow E, Kopelman MD. The National Adult Reading Test as a measure of premorbid intelligence: a comparison with estimates derived from demographic variables. J Int Neuropsychol Soc. 2002;8(6):847-854.
15. Scott TM, Peter I, Tucker KL, Arsenault L, Bergethon P, Bhadelia R, Buell J, Collins L, Dashe JF, Griffith J, Hibberd P, Leins D, Liu T, Ordovas JM, Patz S, Price LL, Qiu WQ, Sarnak M, Selhub J, Smaldone L, Wagner C, Wang L, Weiner D, Yee J, Rosenberg I, Folstein M. The Nutrition, Aging, and Memory in Elders (NAME) study: design and methods for a study of micronutrients and cognitive function in a homebound elderly population. Int J Geriatr Psychiatry. 2006;21(6):519-528.
16. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol. 2003;60(7):958-964.
17. Perez RG, Soriano S, Hayes JD, Ostaszewski B, Xia W, Selkoe DJ, Chen X, Stokin GB, Koo EH. Mutagenesis identifies new signals for beta-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including A42. J Biol Chem. 1999;274(27):18851-18856.
18. Radloff L. The CES-D scale: a self report depression scale for research in the general population. Appl Psychol Meas. 1977;1(3):385-401.
19. Parikh RM, Eden DT, Price TR, Robinson RG. The sensitivity and specificity of the Center for Epidemiologic Studies Depression Scale in screening for poststroke depression. Int J Psychiatry Med. 1988;18(2):169-181.
20. Lahoz C, Osgood D, Wilson PW, Schaefer EJ, Ordovas JM. Frequency of phenotypegenotype discrepancies at the apolipoprotein E locus in a large population study. Clin Chem. 1996;42(11):1817-1823.
21. Arvanitakis Z, Lucas JA, Younkin LH, Younkin SG, Graff-Radford NR. Serum creatinine levels correlate with plasma amyloid beta protein. Alzheimer Dis Assoc Disord. 2002;16(3):187-190.
22. Sun X, Mwamburi DM, Bungay K, Prasad J, Yee J, Lin YM, Liu TC, Summergrad P, Folstein M, Qiu WQ. Depression, antidepressants, and plasma amyloid beta (beta) peptides in those elderly who do not have cardiovascular disease. Biol Psychiatry. 2007;62(12):1413-1417.
23. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303-308.
24. Devanand DP, Sano M, Tang MX, Taylor S, Gurland BJ, Wilder D, Stern Y, Mayeux R. Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Arch Gen Psychiatry. 1996;53(2):175-182.
25. Geerlings MI, Schoevers RA, Beekman AT, Jonker C, Deeg DJ, Schmand B, Adèr HJ, Bouter LM, Van Tilburg W. Depression and risk of cognitive decline and Alzheimer's disease: results of two prospective community-based studies in the Netherlands. Br J Psychiatry. 2000;176:568-575.
26. Paterniti S, Verdier-Taillefer MH, Dufouil C, Alperovitch A. Depressive symptoms and cognitive decline in elderly people: longitudinal study. Br J Psychiatry. 2002;181:406-410.
27. Kumar R, Parslow RA, Jorm AF, Rosenman SJ, Maller J, Meslin C, Anstey KJ, Christensen H, Sachdev PS. Clinical and neuroimaging correlates of mild cognitive impairment in a middle-aged community sample: the Personality and Total Health Through Life 60+ Study. Dement Geriatr Cogn Disord. 2006;21(1):44-50.
28. Berger AK, Fratiglioni L, Forsell Y, Winblad B, Backman L. The occurrence of depressive symptoms in the preclinical phase of AD: a population-based study. Neurology. 1999;53(9):1998-2002.
29. Ritchie K, Ledesert B, Touchon J. Subclinical cognitive impairment: epidemiology and clinical characteristics. Compr Psychiatry. 2000;41(2)(suppl 1):61-65.
30. Cervilla JA, Prince M, Joels S, Mann A. Does depression predict cognitive outcome 9 to 12 years later? evidence from a prospective study of elderly hypertensives. Psychol Med. 2000;30(5):1017-1023.
31. Wilson RS, Barnes LL, Mendes de Leon CF, Aggarwal NT, Schneider JS, Bach J, Pilat J, Beckett LA, Arnold SE, Evans DA, Bennett DA. Depressive symptoms, cognitive decline, and risk of AD in older persons. Neurology. 2002;59(3):364-370.
32. Lopez OL, Becker JT, Sweet RA, Klunk W, Kaufer DI, Saxton J, Habeych M, DeKosky ST. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 2003;15(3):346-353.
33. Rapp MA, Schnaider-Beeri M, Grossman HT, Sano M, Perl DP, Purohit DP, Gorman JM, Haroutunian V. Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry. 2006;63(2):161-167.
34. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the Cardiovascular Health Study. JAMA. 2002;288(12):1475-1483.
35. Geda YE, Knopman DS, Mrazek DA, Jicha GA, Smith GE, Negash S, Boeve BF, Ivnik RJ, Petersen RC, Pankratz VS, Rocca WA. Depression, apolipoprotein E genotype, and the incidence of mild cognitive impairment: a prospective cohort study. Arch Neurol. 2006;63(3):435-440.
36. Elderkin-Thompson V, Thomas MA, Binesh N, Mintz J, Haroon E, Dunkin JJ, Kumar A. Brain metabolites and cognitive function among older depressed and healthy individuals using 2D MR spectroscopy. Neuropsychopharmacology. 2004;29(12):2251-2257.
37. Robinson RG, Bolduc PL, Price TR. Two-year longitudinal study of poststroke mood disorders: diagnosis and outcome at one and two years. Stroke. 1987;18(5):837-843.
38. Alexopoulos GS, Meyers BS, Young RC, Kakuma T, Silbersweig D, Charlson M. Clinically defined vascular depression. Am J Psychiatry. 1997;154(4):562-565.
39. Pomara N, Doraiswamy PM, Willoughby LM, Roth AE, Mulsant BH, Sidtis JJ, Mehta PD, Reynolds CF III, Pollock BG. Elevation in plasma Aβ42 in geriatric depression: a pilot study. Neurochem Res. 2006;31(3):341-349.
40. Qiu WQ, Summergrad P, Folstein M. Plasma Aβ42 levels and depression in the elderly. Int J Geriatr Psychiatry. 2007;22(9):930.
41. Selkoe DJ. The ups and downs of Aβ. Nat Med. 2006;12(7):758-759.
42. Zhang-Nunes SX, Maat-Schieman ML, van Duinen SG, Roos RA, Frosch MP, Greenberg SM. The cerebral beta-amyloid angiopathies: hereditary and sporadic. Brain Pathol. 2006;16(1):30-39.
43. Chen M, Inestrosa NC, Ross GS, Fernandez HL. Platelets are the primary source of amyloid β-peptide in human blood. Biochem Biophys Res Commun. 1995;213(1):96-103.
44. Casoli T, Di Stefano G, Giorgetti B, Grossi Y, Balietti M, Fattoretti P, Bertoni-Freddari C. Release of β-amyloid from high-density platelets: implications for Alzheimer's disease pathology. Ann N Y Acad Sci. 2007;1096:170-178.
45. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ. Insulin-degrading enzyme regulates extracellular levels of amyloid β-protein by degradation. J Biol Chem. 1998;273(49):32730-32738.
46. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC. Metabolic regulation of brain Abeta by neprilysin. Science. 2001;292(5521):1550-1552.
47. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 2002;295(5563):2264-2267.
48. Longstreth WT Jr, Manolio TA, Arnold A, Burke GL, Bryan N, Jungreis CA, Enright PL, O'Leary D, Fried L. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people: the Cardiovascular Health Study. Stroke. 1996;27(8):1274-1282.
49. de Groot JC, de Leeuw FE, Oudkerk M, Hofman A, Jolles J, Breteler MM. Cerebral white matter lesions and depressive symptoms in elderly adults. Arch Gen Psychiatry. 2000;57(11):1071-1076.
50. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348(13):1215-1222.
51. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease: the Nun Study. JAMA. 1997;277(10):813-817.
52. Heyman A, Fillenbaum GG, Welsh-Bohmer KA, Gearing M, Mirra SS, Mohs RC, Peterson BL, Pieper CF. Cerebral infarcts in patients with autopsy-proven Alzheimer's disease: CERAD, part XVIII: Consortium to Establish a Registry for Alzheimer's Disease. Neurology. 1998;51(1):159-162.
53. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol. 2000;57(1):100-105.
54. Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, Mehta PD. Plasma Aβ40 and Aβ42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology. 2003;61(9):1185-1190.
55. Mayeux R, Tang MX, Jacobs DM, Manly J, Bell K, Merchant C, Small SA, Stern Y, Wisniewski HM, Mehta PD. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol. 1999;46(3):412-416.
56. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996;2(8):864-870.
57. Mehta PD, Mehta SP, Fedor B, Patrick BA, Emmerling M, Dalton AJ. Plasma amyloid β protein 1-42 levels are increased in old Down syndrome but not in young Down syndrome. Neurosci Lett. 2003;342(3):155-158.
58. Mehta PD, Capone G, Jewell A, Freedland RL. Increased amyloid β protein levels in children and adolescents with Down syndrome. J Neurol Sci. 2007;254 (1-2):22-27.
59. 42 levels, incident dementia, and mortality in Down syndrome. Arch Neurol. 2007;64(7):1007-1013.
60. Assini A, Cammarata S, Vitali A, Colucci M, Giliberto L, Borghi R, Inglese ML, Volpe S, Ratto S, Dagna-Bricarelli F, Baldo C, Argusti A, Odetti P, Piccini A, Tabaton M. Plasma levels of amyloid β-protein 42 are increased in women with mild cognitive impairment. Neurology. 2004;63(5):828-831.
61. Pomara N, Murali Doraiswamy P. Does increased platelet release of Aβ peptide contribute to brain abnormalities in individuals with depression? Med Hypotheses. 2003;60(5):640-643.
62. Zetterberg H, Blennow K. Plasma Aβ in Alzheimer's disease: up or down? Lancet Neurol. 2006;5(8):638-639.
63. Oprisiu R, Serot JM, Godefroy O, Black SE, Fournier A. Plasma amyloid-β concentrations in Alzheimer's disease: an alternative hypothesis. Lancet Neurol. 2006;5(12):1001-1002.